Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIVIK: Continuous vs Intermittent Ketorolac in Pediatric Cardiac Surgery
NCT04040452Phase 4Recruiting
- Sponsor
- Phoenix Children's
- Start
- Mar 2021
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ketorolac in postoperative pain (2 arms), sponsored by Phoenix Children's. Primary endpoint: Total fentanyl dose equivalents received within the first 96 hours post-operatively at 72 hours. Started Mar 2021; status: recruiting.
02
Drugs
ketorolac
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04040452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040452.